MT-1303 High dose ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02307643 (ClinicalTrials.gov) | February 2015 | 18/11/2014 | Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients | An Exploratory Study of MT-1303 in Subjects With Systemic Lupus Erythematosus (a Multicenter, Open-label Study) | Systemic Lupus Erythematosus | Drug: MT-1303 Low dose;Drug: MT-1303 High dose | Mitsubishi Tanabe Pharma Corporation | NULL | Completed | 20 Years | 64 Years | All | 17 | Phase 1 | Japan |